Compositions and methods for modulating the immune system
A novel class of embryo derived peptides are described (Preimplantation factor) that were generated synthetically and were tested on peripheral blood immune cells and shown to block activated but not basal immunity, inhibiting cell proliferation and creating a T H 2 type cytokine bias, in addition PIF enhance endometrial receptivity by increasing adhesion molecules expression. PIF biological activity appears to be exerted by specific binding to inducible receptors present on the several white cell lineages. PIF peptides, which are immune modulators therefore may have diagnostic and non toxic therapeutic applications in improving fertility, reducing pregnancy loss as well may be useful when administered for the treatment of autoimmune diseases and for prevention xenotransplants rejection.
1. A method of treating graft-versus-host disease (GVHD) in a subject in need thereof comprising administering a therapeutically effective amount of a PIF peptide, wherein the PIF peptide is administered parenterally, orally, or topically, and wherein the PIF peptide is selected from the group consisting of SEQ ID NO: 13, SEQ ID NO: 16, SEQ ID NO: 18, and SEQ ID NO: 19.
2. The method of claim 1 , wherein said PIF peptide is SEQ ID NO: 13.
3. The method of claim 1 , wherein the subject has had a bone marrow transplant.
4. The method of claim 3 , wherein the bone marrow transplant is an allogenic bone marrow transplant.
5. The method of claim 1 , wherein the subject has been exposed to radiation.
6. The method of claim 1 , wherein the PIF peptide is administered subcutaneously.
7. The method of claim 1 , wherein the PIF peptide is administered intravenously or intramuscularly.
8. A method of treating a subject, the method comprising:
exposing the subject to radiation; and
administering a therapeutically effective amount of a PIF peptide to the subject,
wherein the PIF peptide is selected from the group consisting of SEQ ID NO: 13, SEQ ID NO: 16, SEQ ID NO: 18, and SEQ ID NO: 19, and wherein the subject has had a bone marrow transplant.
9. The method of claim 8 , wherein said PIF peptide is SEQ ID NO: 13.
10. The method of claim 8 , wherein said therapeutically effective amount is from about 0.01 mg/kg to about 10 mg/kg.
11. The method of claim 8 , wherein the PIF peptide is administered subcutaneously.
12. The method of claim 8 , wherein the PIF peptide is administered intravenously or intramuscularly.
13. A method of treating a subject, the method comprising:
performing a bone marrow transplant on the subject; and
administering a therapeutically effective amount of a PIF peptide to the subject,
wherein the PIF peptide is selected from the group consisting of SEQ ID NO: 13, SEQ ID NO: 16, SEQ ID NO: 18, and SEQ ID NO: 19.
14. The method of claim 13 , wherein said PIF peptide is SEQ ID NO: 13.
15. The method of claim 13 , wherein the method further comprises exposing the subject to radiation prior to the administration step.
16. The method of claim 13 , wherein the PIF peptide is administered subcutaneously.
17. The method of claim 13 , wherein the PIF peptide is administered intravenously or intramuscularly.